Skip to main content
SpringerLink
Log in

Epidemiology and burden of illness of rheumatoid arthritis

  • Original Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects more women than men. The magnitude of the severe long-term economic consequences of RA has been underestimated in the past. Most patients with the disease require continuous treatment to retard or stop progression and to control disease flares. Many also require surgery, such as total hip or knee replacement. In addition to these direct costs, work disability leads to reduced productivity and early retirement, and as a result, substantial indirect costs. The individual and his or her family must cope with the feeling of loss of contribution to society combined with redefined social roles, and the effects of pain, fatigue, low self-esteem, mental distress and depression.

A number of countries in North America and Europe have reported a decline in the incidence of RA in recent years, although geographical differences remain that may be associated with genetic, environmental or cultural factors. Nevertheless, patients with RA have not shared the improvements in survival rates seen with other diseases over the last 40 years, and have a mean reduction in life expectancy of between 5 and 10 years. Disease severity, activity and disability are strongly linked to premature mortality in patients with RA. The high direct and indirect costs associated with RA, together with the substantial morbidity and mortality affecting millions of people worldwide, underline the potential benefits of improved treatments for this chronic disease to patients, their families and society.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

References

  1. Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 2001; 19 (8): 811–8

    Article  PubMed  CAS  Google Scholar 

  2. Hunsche E, Chancellor JV, Bruce N. The burden of arthritis and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics 2001; 19 Suppl. 1: 1–15

    Article  PubMed  Google Scholar 

  3. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995; 50 Suppl. 1: 1–14

    Article  PubMed  Google Scholar 

  4. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31 (3): 315–24

    Article  PubMed  CAS  Google Scholar 

  5. Abdel-Nasser AM, Rasker JJ, Valkenburg HA. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 1997; 27 (2): 123–40

    Article  PubMed  CAS  Google Scholar 

  6. Isomäki HA. Prevalence and social impact of rheumatic diseases in Finland. J Rheumatol 1983; 10 Suppl.: 29–33

    Google Scholar 

  7. Knorr U. [A panorama of rheumatic diseases]. Versicherungsmedizin 1994; 46 (6): 212–5

    PubMed  CAS  Google Scholar 

  8. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41 (5): 778–99

    Article  PubMed  CAS  Google Scholar 

  9. Rubin LA and Voorneveld CR. High prevalence of rheumatoid arthritis among North American Native Indians (NANI): support for the New World theory of RA. Arthritis Rheum 1991; 34 Suppl. 9: S181

    Google Scholar 

  10. Boyer GS, Templin DW, Lanier AP. Rheumatic diseases in Alaskan Indians of the southeast coast: high prevalence of rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 1991; 18 (10): 1477–84

    PubMed  CAS  Google Scholar 

  11. Boyer GS, Benevolenskaya LI, Templin DW, et al. Prevalence of rheumatoid arthritis in circumpolar native populations. J Rheumatol 1998; 25 (1): 23–9

    PubMed  CAS  Google Scholar 

  12. Del Puente A, Knowler WC, Pettitt DJ, Bennett PH. High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am J Epidemiol 1989; 129 (6): 1170–8

    PubMed  Google Scholar 

  13. Guillemin F, Briancon S, Klein JM, Sauleau E, Pourel J. Low incidence of rheumatoid arthritis in France. Scand J Rheumatol 1994; 23 (5): 264–8

    Article  PubMed  CAS  Google Scholar 

  14. Gran JT, Magnus J, Mikkelsen K. The incidence of classical and definite rheumatoid arthritis in Lillehammer, Norway. Scand J Rheumatol 1986; 15 Suppl. 59: 7–11

    Google Scholar 

  15. Uhlig T, Kvien TK, Glennas A, Smedstad LM, Forre O. The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J Rheumatol 1998; 25 (6): 1078–84

    PubMed  CAS  Google Scholar 

  16. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33 (8): 735–9

    Article  PubMed  CAS  Google Scholar 

  17. Doran MF, Pond GR, Crowson CS, O’Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum 2002; 46 (3): 625–31

    Article  PubMed  Google Scholar 

  18. Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999; 42 (3): 415–20

    Article  PubMed  CAS  Google Scholar 

  19. Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84 (3): 223–43

    Article  PubMed  CAS  Google Scholar 

  20. Chan KW, Felson DT, Yood RA, Walker AM. Incidence of rheumatoid arthritis in central Massachusetts. Arthritis Rheum 1993; 36 (12): 1691–6

    Article  PubMed  CAS  Google Scholar 

  21. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987–1989. Arthritis Rheum 1991; 34 (12): 1502–7

    Article  PubMed  CAS  Google Scholar 

  22. Linos A, Worthington JW, O’Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980; 111 (1): 87–98

    PubMed  CAS  Google Scholar 

  23. Jacobsson LT, Hanson RL, Knowler WC, et al. Decreasing incidence and prevalence of rheumatoid arthritis in Pima Indians over a twenty-five-year period. Arthritis Rheum 1994; 37 (8): 1158–65

    Article  PubMed  CAS  Google Scholar 

  24. Wiles N, Symmons DP, Harrison B, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999; 42 (7): 1339–46

    Article  PubMed  CAS  Google Scholar 

  25. Kvien TK, Glennas A, Knudsrod OG, Smedstad LM, Mowinckel P, Forre O. The prevalence and severity of rheumatoid arthritis in Oslo. Results from a county register and a population survey. Scand J Rheumatol 1997; 26 (6): 412–8

    Article  PubMed  CAS  Google Scholar 

  26. Wiles NJ, Lunt M, Barrett EM, et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 2001; 44 (5): 1033–42

    Article  PubMed  CAS  Google Scholar 

  27. Bukhari MA, Wiles NJ, Lunt M, et al. Influence of diseasemodifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48 (1): 46–53

    Article  PubMed  CAS  Google Scholar 

  28. Mottonen T, Hannonen P, Korpela M, et al. Delay to institution of therapy and induction of remission using singledrug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46 (4): 894–8

    Article  PubMed  CAS  Google Scholar 

  29. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111 (6): 446–51

    Article  PubMed  CAS  Google Scholar 

  30. Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998; 37 (11): 1157–63

    Article  PubMed  CAS  Google Scholar 

  31. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995; 22 (12): 2208–13

    PubMed  CAS  Google Scholar 

  32. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996; 124 (8): 699–707

    PubMed  Google Scholar 

  33. Buckwalter JA and Lappin DR. The disproportionate impact of chronic arthralgia and arthritis among women. Clin Orthop 2000 (372): 159–68

    Google Scholar 

  34. James WH. Rheumatoid arthritis, the contraceptive pill, and androgens. Ann Rheum Dis 1993; 52 (6): 470–4

    Article  PubMed  CAS  Google Scholar 

  35. Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. Ann Rheum Dis 1993; 52 (3): 211–4

    Article  PubMed  CAS  Google Scholar 

  36. Valentino R, Savastano S, Tommaselli AP, et al. Hormonal pattern in women affected by rheumatoid arthritis. J Endocrinol Invest 1993; 16 (8): 619–24

    PubMed  CAS  Google Scholar 

  37. Brennan P and Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994; 37 (6): 808–13

    Article  PubMed  CAS  Google Scholar 

  38. Katz PP and Criswell LA. Differences in symptom reports between men and women with rheumatoid arthritis. Arthritis Care Res 1996; 9 (6): 441–8

    Article  PubMed  CAS  Google Scholar 

  39. Hochberg MC. Changes in the incidence and prevalence of rheumatoid arthritis in England and Wales, 1970–1982. Semin Arthritis Rheum 1990; 19 (5): 294–302

    Article  PubMed  CAS  Google Scholar 

  40. Kaipiainen-Seppänen O, Aho K, Isomäki HA, Laakso M. Incidence of rheumatoid arthritis in Finland during 1980–1990. Ann Rheum Dis 1996; 55 (9): 608–11

    Article  PubMed  Google Scholar 

  41. Shichikawa K, Inoue K, Hirota S, et al. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965–1996. Ann Rheum Dis 1999; 58 (12): 751–6

    Article  PubMed  CAS  Google Scholar 

  42. Hazes JM, Dijkmans BC, Vandenbroucke JP, de Vries RR, Cats A. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum 1990; 33 (2): 173–9

    Article  PubMed  CAS  Google Scholar 

  43. Riise T, Jacobsen BK, Gran JT. Incidence and prevalence of rheumatoid arthritis in the county of Troms, northern Norway. J Rheumatol 2000; 27 (6): 1386–9

    PubMed  CAS  Google Scholar 

  44. Imanaka T, Shichikawa K, Inoue K, Shimaoka Y, Takenaka Y, Wakitani S. Increase in age at onset of rheumatoid arthritis in Japan over a 30 year period. Ann Rheum Dis 1997; 56 (5): 313–6

    Article  PubMed  CAS  Google Scholar 

  45. Kaipiainen-Seppanen O, Aho K, Isomaki H, Laakso M. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975–1990. Clin Exp Rheumatol 1996; 14 (5): 537–42

    PubMed  CAS  Google Scholar 

  46. Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002; 47 (4): 391–7

    Article  PubMed  Google Scholar 

  47. Smedstad LM, Moum T, Guillemin F, et al. Correlates of functional disability in early rheumatoid arthritis: a crosssectional study of 706 patients in four European countries. Br J Rheumatol 1996; 35 (8): 746–51

    Article  PubMed  CAS  Google Scholar 

  48. Smedstad LM, Moum T, Vaglum P, Kvien TK. The impact of early rheumatoid arthritis on psychological distress. A comparison between 238 patients with RA and 116 matched controls. Scand J Rheumatol 1996; 25 (6): 377–82

    Article  PubMed  CAS  Google Scholar 

  49. Smedstad LM, Vaglum P, Moum T, Kvien TK. The relationship between psychological distress and traditional clinical variables: a 2 year prospective study of 216 patients with early rheumatoid arthritis. Br J Rheumatol 1997; 36 (12): 1304–11

    Article  PubMed  CAS  Google Scholar 

  50. Sharpe L, Sensky T, Allard S. The course of depression in recent onset rheumatoid arthritis: the predictive role of disability, illness perceptions, pain and coping. J Psychosom Res 2001; 51 (6): 713–9

    Article  PubMed  CAS  Google Scholar 

  51. Wright GE, Parker JC, Smarr KL, et al. Risk factors for depression in rheumatoid arthritis. Arthritis Care Res 1996; 9 (4): 264–72

    Article  PubMed  CAS  Google Scholar 

  52. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gillis CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Rsch 1993; 2 (2): 93–9

    Google Scholar 

  53. Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol 1998; 37 (10): 1042–6

    Article  PubMed  CAS  Google Scholar 

  54. Fifield J, McQuillan J, Tennen H, et al. History of affective disorder and the temporal trajectory of fatigue in rheumatoid arthritis. Ann Behav Med 2001; 23 (1): 34–41

    Article  PubMed  CAS  Google Scholar 

  55. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23 (8): 1407–17

    PubMed  CAS  Google Scholar 

  56. Belza BL. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995; 22 (4): 639–43

    PubMed  CAS  Google Scholar 

  57. Dadoniene J, Uhlig T, Stropuviene S, Venalis A, Boonen A, Kvien TK. Disease activity and health status in rheumatoid arthritis: a case-control comparison between Norway and Lithuania. Ann Rheum Dis 2003; 62 (3): 231–5

    Article  PubMed  CAS  Google Scholar 

  58. Kvien TK, Uhlig T, Kristiansen IS. Patients with rheumatoid arthritis (RA) are gaining quality adjusted life years (QALYs) with access to new therapies. Arthritis Rheum 2002; 46 Suppl. 342

    Google Scholar 

  59. Pincus T, Swearingen C, Gibson M, Sokka T. Is rheumatoid arthritis becoming a (slightly) milder disease? Improvement in hematologic status of patients with rheumatoid arthritis between 1982 and 2001. Arthritis Rheum 2002; 46 Suppl.: 833

    Google Scholar 

  60. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37 (4): 481–94

    Article  PubMed  CAS  Google Scholar 

  61. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002; 29: 1851–7

    PubMed  Google Scholar 

  62. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29 (6): 706–14

    Article  PubMed  CAS  Google Scholar 

  63. Symmons DP, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 1998; 25 (6): 1072–7

    PubMed  CAS  Google Scholar 

  64. Wållberg-Jonsson S, Öhman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24 (3): 445–51

    PubMed  Google Scholar 

  65. Riise T, Jacobsen BK, Gran JT, Haga HJ, Arnesen E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol 2001; 20 (2): 123–7

    Article  PubMed  CAS  Google Scholar 

  66. Gabriel SE, Crowson CS, O’Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999; 26 (12): 2529–33

    PubMed  CAS  Google Scholar 

  67. Chehata JC, Hassell AB, Clarke SA, et al. Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity. Rheumatology 2001; 40: 447–52

    Article  PubMed  CAS  Google Scholar 

  68. Myllykangas-Luosujarvi R, Aho K, Kautiainen H, Isomäki HA. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 1995; 13 (2): 149–53

    PubMed  CAS  Google Scholar 

  69. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 28–33

    Article  PubMed  CAS  Google Scholar 

  70. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513–22

    Article  PubMed  CAS  Google Scholar 

  71. Jonsson B, Rehnberg C, Borgquist L, Larsson SE. Locomotion status and costs in destructive rheumatoid arthritis. A comprehensive study of 82 patients from a population of 13,000. Acta Orthopaedica Scandinavica 1992; 63 (2): 207–12

    Article  PubMed  CAS  Google Scholar 

  72. Meenan RF, Yelin EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21 (7): 827–33

    Article  PubMed  CAS  Google Scholar 

  73. Doyle JJ. Economic and quality-of-life impact of rheumatoid arthritis. Managed Care 2001; 10 Suppl. 7: 15–8

    PubMed  CAS  Google Scholar 

  74. Gabriel SE, Crowson CS, Campion ME, O’Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997; 24 (1): 719–25

    PubMed  CAS  Google Scholar 

  75. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986; 29 (4): 488–93

    Article  PubMed  CAS  Google Scholar 

  76. Meenan RF, Yelin EH, Nevitt M, Epstein WV. The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum 1981; 24 (3): 544–9

    Article  PubMed  CAS  Google Scholar 

  77. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 1997; 40 (8): 1475–81

    Article  PubMed  CAS  Google Scholar 

  78. Yelin E and Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999; 42 (6): 1209–18

    Article  PubMed  CAS  Google Scholar 

  79. Clarke AE, Zowall H, Levinton C, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24 (6): 1051–60

    PubMed  CAS  Google Scholar 

  80. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol 1996; 44 Suppl.: 47–51

    CAS  Google Scholar 

  81. Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicenter study of hospitalization in rheumatoid arthritis: effect of health care system, severity, and regional difference. J Rheumatol 1986; 13 (2): 277–84

    PubMed  CAS  Google Scholar 

  82. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35 (8): 781–90

    Article  PubMed  CAS  Google Scholar 

  83. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Heurkens AH, Haanen HC, Bijlsma JW. Direct cost of rheumatoid arthritis during the first six years: a cost-of-illness study. Br J Rheumatol 1998; 37 (8): 837–47

    Article  PubMed  Google Scholar 

  84. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42 (2): 347–56

    Article  PubMed  CAS  Google Scholar 

  85. van Jaarsveld CH, Jacobs JW, Schrijvers AJ, Van Albada-Kuipers GA, Hofman DM, Bijlsma JW. Effects of rheumatoid arthritis on employment and social participation during the first years of disease in the Netherlands. Br J Rheumatol 1998; 37 (8): 848–53

    Article  PubMed  Google Scholar 

  86. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26 (8): 1681–5

    PubMed  CAS  Google Scholar 

  87. Merkesdal S, Ruof J, Schoffski O, Bernitt K, Zeidler H, Mau W. Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 2001; 44 (3): 528–34

    Article  PubMed  CAS  Google Scholar 

  88. Newhall-Perry K, Law NJ, Ramos B, Sterz M, Wong WK. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. J Rheumatol 2000; 27: 1156–63

    PubMed  CAS  Google Scholar 

  89. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a twocountry model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum 2002; 46 (9): 2310–9

    Article  PubMed  Google Scholar 

  90. Gabriel SE, Crowson CS, Campion ME, O’Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24 (1): 43–8

    PubMed  CAS  Google Scholar 

  91. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000; 42 (6): 588–96

    Article  PubMed  CAS  Google Scholar 

  92. Young A, Dixey J, Kulinskaya E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis 2002; 61 (4): 335–40

    Article  PubMed  CAS  Google Scholar 

  93. The burden of rheumatoid arthritis. Based on a presentation by Frederick Wolfe, MD. Am J Manag Care 1999; 5 Suppl. 14: S852–9; discussion S866-9

  94. Gabriel SE, Crowson CS, Luthra HS, Wagner JL, O’Fallon WM. Modeling the lifetime costs of rheumatoid arthritis. J Rheumatol 1999; 26: 1269–74

    PubMed  CAS  Google Scholar 

  95. Aho K, Heliovaara M, Sievers K, Maatela J, Isomäki H. Clinical arthritis associated with positive radiological and serological findings in Finnish adults. Rheumatol Int 1989; 9 (1): 7–11

    Article  PubMed  CAS  Google Scholar 

  96. Aho K, Kaipiainen-Seppänen O, Heliövaara M, Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998; 27 (5): 325–34

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This study was supported by a grant from Wyeth.

Author information

Authors and Affiliations

  1. Oslo City Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, Oslo, N-0319, Norway

    Tore K. Kvien

Authors
  1. Tore K. Kvien
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tore K. Kvien.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kvien, T.K. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomic 22 (Suppl 1), 1–12 (2004). https://doi.org/10.2165/00019053-200422001-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200422001-00002

Keywords

Search

Navigation